2450 HOLCOMBE BLVD, HOUSTON, TX
Issues Correction to Warrant Inducement Transaction Press Release
Decoy Therapeutics Inc. Approves Common Stock Issuance and Share Reduction
2026 Annual Meeting Results; Directors Elected and Compensation Approved
Investor Presentation
Material disclosure
Announces 1-for-12 Reverse Stock Split
Stockholders Approve 2026 Equity Incentive Plan at Special Meeting
Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
Q2
Q1
Amended Annual Report
FY 2025
Q3
FY 2024
S-1
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
RW
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
PRE 14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload